- Home
- OCUL vs XNCR Comparison
OCUL vs XNCR Comparison
Compare OCUL & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OCUL | XNCR |
|---|---|---|
| Founded | 2006 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.0B |
| IPO Year | 2014 | 2013 |
Fundamental Metrics
Financial Performance| Metric | OCUL | XNCR |
|---|---|---|
| Price | $10.42 | $26.37 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 9 |
| Target Price | ★ $23.56 | $22.33 |
| AVG Volume (30 Days) | ★ 2.6M | 1.3M |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 65.36 |
| EPS | ★ N/A | N/A |
| Revenue | $1,990,000.00 | ★ $125,576,000.00 |
| Revenue This Year | $7.93 | N/A |
| Revenue Next Year | $96.07 | $4.80 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 3.48 | ★ 13.65 |
| 52 Week Low | $6.23 | $8.29 |
| 52 Week High | $16.44 | $30.61 |
Technical Indicators
Market Signals| Indicator | OCUL | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 55.83 | 57.44 |
| Support Level | $7.96 | $11.20 |
| Resistance Level | $10.78 | $30.61 |
| Average True Range (ATR) | 0.50 | 1.71 |
| MACD | -0.05 | -0.33 |
| Stochastic Oscillator | 30.75 | 45.14 |
Price Performance
Historical ComparisonAbout OCUL Ocular Therapeutix Inc.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
About XNCR Xencor Inc.
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.